MASS News & Events

Reports Q1 revenue $13.4M, consensus $13.16M. "We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion," said Kevin J. Knopp, CEO and Co-founder. "We are also excited to announce the acquisition of NIRLAB AG, a strategic transaction that broadens our reach into the lower-cost, widely-deployable segment of the narcotics detection market while increasing our recurring revenue opportunity through software subscriptions. This transaction reflects our focus on disciplined growth investments as we continue to execute our transformation strategy."

908 Devices announced that it has completed the acquisition of NIRLAB AG, a privately held company based in Lausanne, Switzerland. The company delivers AI-powered, cloud-connected near-infrared spectroscopy to perform handheld chemical analysis of narcotics in seconds. "We're thrilled to welcome the NIRLAB team to 908 Devices. Our combination creates a powerful end-to-end workflow advantage for our law enforcement customers," said Kevin J. Knopp, CEO and Co-founder of 908 Devices. "From fast, simple screening to trace-level analysis to detection of a broad range of substances, we offer a comprehensive solution for field-based chemical identification." The purchase consideration includes an upfront payment of $15 million, consisting of $13 million in cash and $2 million of 908 Devices common stock. The purchase agreement also includes up to an additional $8 million in 908 Devices common stock upon the achievement of performance milestones over the next 20 months.